This K24 application is to provide support for protected time for: 1) mentoring/teaching of junior clinical investigators;and 2) patient-oriented research investigating the role of aldosterone in the pathophysiology of diabetic cardiovascular disease. Recent data provide support for the hypothesis that activation of the mineralocorticoid receptor (MR) contributes to diabetic vascular injury, though the mechanisms are uncertain. Consistent with this hypothesis, our pre-clinical studies demonstrate that blockade of MR reduces renal injury in diabetic db/db mice and reduces vascular inflammation and cardiac and renal injury in hypertensive, angiotensin II (ANGII)-infused rodents. Our clinical studies show that short-term treatment with the MR antagonist eplerenone improves coronary circulatory function as compared to treatment with hydrochlorothiazide (HCTZ) in subjects with diabetes receiving angiotensin-converting enzyme (ACE) inhibition therapy. This observation could not be attributed to blood pressure changes suggesting that MR antagonists are not working via a classical renal effect, but via an additional, volume control-independent mechanism. This proposal tests the hypotheses that MR activation contributes to progression of vascular disease in subjects with type 2 diabetes mellitus (T2DM) receiving ACE inhibitor therapy, and consequently, MR antagonists exert beneficial effects by reducing vascular dysfunction and injury, inhibiting ANGII vascular effects, improving coronary circulatory and cardiac function and improving renovascular function. To address these hypotheses we will perform a prospective double-blind study in subjects with T2DM and hypertension receiving chronic ACE inhibitor therapy randomized to one of three treatments: 1) MR antagonist spironolactone;2) HCTZ plus potassium;and 3) placebo. These studies provide a fertile area for investigation by trainees interested in patient-oriented research and will provide new information about the mechanisms by which MR antagonists reduce diabetic cardiovascular injury, with the goal of introducing new, effective treatments of cardiovascular injury in individuals with diabetes.

Public Health Relevance

This grant application seeks support for the training and mentoring of a new generation of physicians and investigators interested in performing research in patients with diabetes and heart disease. Diabetes causes injury to blood vessels. This injury leads to many health problems including heart disease, kidney failure and stroke. The goal of this research is to determine whether blocking the actions of a hormone known as aldosterone improves the function of vessels in the hearts and kidneys of patients with type 2 diabetes and whether this leads to improvements in heart and kidney function. Thus, this research may lead to new treatments for patients with diabetes and injury to their hearts and kidneys, and will provide a forum for mentoring trainees in patient-oriented research.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24HL103845-04
Application #
8661245
Study Section
Special Emphasis Panel (ZHL1-CSR-X (F1))
Program Officer
Carlson, Drew E
Project Start
2011-05-02
Project End
2016-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
4
Fiscal Year
2014
Total Cost
$200,660
Indirect Cost
$14,864
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Dean 2nd, Dennis A; Adler, Gail K; Nguyen, David P et al. (2014) Biological time series analysis using a context free language: applicability to pulsatile hormone data. PLoS One 9:e104087
Brown, Jenifer M; Underwood, Patricia C; Ferri, Claudio et al. (2014) Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Hypertension 63:1205-11
Brown, Jenifer M; Williams, Jonathan S; Luther, James M et al. (2014) Human interventions to characterize novel relationships between the renin-angiotensin-aldosterone system and parathyroid hormone. Hypertension 63:273-80
Faghih, Rose T; Dahleh, Munther A; Adler, Gail K et al. (2014) Deconvolution of serum cortisol levels by using compressed sensing. PLoS One 9:e85204
Garg, R; Kneen, L; Williams, G H et al. (2014) Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab 16:268-72
Baudrand, R; Lian, C G; Lian, B Q et al. (2014) Long-term dietary sodium restriction increases adiponectin expression and ameliorates the proinflammatory adipokine profile in obesity. Nutr Metab Cardiovasc Dis 24:34-41
Vaidya, Anand; Underwood, Patricia C; Hopkins, Paul N et al. (2013) Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 61:886-93
Krug, Alexander W; Stelzner, Lissy; Rao, Ajaykumar D et al. (2013) Effect of low dose mineralocorticoid receptor antagonist eplerenone on glucose and lipid metabolism in healthy adult males. Metabolism 62:386-91
Rao, A D; Sun, B; Saxena, A et al. (2013) Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. J Hum Hypertens 27:176-80
Underwood, Patricia C; Adler, Gail K (2013) The renin angiotensin aldosterone system and insulin resistance in humans. Curr Hypertens Rep 15:59-70

Showing the most recent 10 out of 11 publications